131 related articles for article (PubMed ID: 8513846)
1. Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
Gladziwa U; Wagner S; Dakshinamurty KV; el Desoky E; Dreuw B; Klotz U
Eur J Clin Pharmacol; 1993; 44(4):357-60. PubMed ID: 8513846
[TBL] [Abstract][Full Text] [Related]
2. Famotidine in the management of acid-reflux oesophagitis: a multicentre study.
Bovero E; Poletti M; Iaquinto G; Giardulo N; Zambelli A; Pisano G; Cheli R
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():145-8. PubMed ID: 2083926
[TBL] [Abstract][Full Text] [Related]
3. Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists.
Bianchi Porro G; Pace F; Sangaletti O
Scand J Gastroenterol; 1990 Aug; 25(8):810-4. PubMed ID: 1976270
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid.
Oderda G; Dell'Olio D; Forni M; Farina L; Tavassoli K; Ansaldi N
Ital J Gastroenterol; 1990 Dec; 22(6):346-9. PubMed ID: 2131953
[TBL] [Abstract][Full Text] [Related]
5. Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
Ahmed W; Qureshi H; Alam SE; Zuberi SJ
J Pak Med Assoc; 1995 Sep; 45(9):241-3. PubMed ID: 8683830
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Vasil'ev IuV; Li IA
Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis.
Sekiguchi T; Nishioka T; Matsuzaki T; Sugiyama M; Kusano M; Horikoshi T; Toki M; Ohwada T; Kobayashi S
Gastroenterol Jpn; 1991 Apr; 26(2):137-44. PubMed ID: 2040397
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview.
Dammann HG
Hepatogastroenterology; 1990 Jul; 37 Suppl 1():2-5. PubMed ID: 2210612
[TBL] [Abstract][Full Text] [Related]
9. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.
Inauen W; Emde C; Weber B; Armstrong D; Bettschen HU; Huber T; Scheurer U; Blum AL; Halter F; Merki HS
Gut; 1993 Aug; 34(8):1025-31. PubMed ID: 8174947
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis. Dutch Esophagitis Study Group.
Wesdorp IC; Dekker W; Festen HP
Clin Ther; 1997; 19(5):1048-57. PubMed ID: 9385492
[TBL] [Abstract][Full Text] [Related]
11. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Langtry HD; Grant SM; Goa KL
Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
[TBL] [Abstract][Full Text] [Related]
12. Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp IC
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():24-6. PubMed ID: 1577391
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.
James LP; Kearns GL
Clin Pharmacokinet; 1996 Aug; 31(2):103-10. PubMed ID: 8853932
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
Nagita A; Manago M; Aoki S; Mino M; Suzuki K; Ashida K
Ther Drug Monit; 1994 Oct; 16(5):444-9. PubMed ID: 7846741
[TBL] [Abstract][Full Text] [Related]
15. On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life.
Wilhelmsen I; Hatlebakk JG; Olafsson S; Berstad A
Aliment Pharmacol Ther; 1999 Aug; 13(8):1035-40. PubMed ID: 10468678
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of famotidine in children.
James LP; Marshall JD; Heulitt MJ; Wells TG; Letzig L; Kearns GL
J Clin Pharmacol; 1996 Jan; 36(1):48-54. PubMed ID: 8932543
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the effects between standard doses of H2-blocker (famotidine 20mg b.d.) and proton pump inhibitor (omeprazole 20mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring].
Yamashita Y; Kinoshita Y; Chihara K; Chiba T
Nihon Shokakibyo Gakkai Zasshi; 1994 Dec; 91(12):2166-73. PubMed ID: 7837683
[TBL] [Abstract][Full Text] [Related]
19. Famotidine in the management of gastro-oesophageal reflux.
Okoth FA; Lule GN; Ogutu EO; Pilczer S; Dubois C
East Afr Med J; 1994 Jan; 71(1):44-8. PubMed ID: 8055765
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial.
Kim EH; Lee YC; Chang YW; Park JJ; Chun HJ; Jung HY; Kim HS; Jeong HY; Seol SY; Han SW; Choi MG; Park SH; Lee OJ; Jung JT; Lee DH; Jung HC; Lee ST; Kim JG; Youn SJ; Kim HY; Lee SW
Dig Dis Sci; 2015 Jun; 60(6):1724-32. PubMed ID: 25532503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
